Cargando…

Liraglutide, a glucagon-like peptide 1 receptor agonist, exerts analgesic, anti-inflammatory and anti-degradative actions in osteoarthritis

Osteoarthritis (OA) is a common disabling disease worldwide, with no effective and safe disease-modifying drugs (DMOAD) in the market. However, studies suggest that drugs, such as liraglutide, which possess strong potential in decreasing low-grade systemic inflammation may be effective in treating O...

Descripción completa

Detalles Bibliográficos
Autores principales:	Meurot, C., Martin, C., Sudre, L., Breton, J., Bougault, C., Rattenbach, R., Bismuth, K., Jacques, C., Berenbaum, F.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8799666/ https://www.ncbi.nlm.nih.gov/pubmed/35091584 http://dx.doi.org/10.1038/s41598-022-05323-7

Ejemplares similares

Targeting the GLP-1/GLP-1R axis to treat osteoarthritis: A new opportunity?
por: Meurot, C., et al.
Publicado: (2022)

Glucagon-Like Peptide-1 Receptor Agonist Liraglutide Ameliorates the Development of Periodontitis
por: Sawada, Noritaka, et al.
Publicado: (2020)

The glucagon‐like peptide 1 receptor agonist liraglutide attenuates the reinforcing properties of alcohol in rodents
por: Vallöf, Daniel, et al.
Publicado: (2015)

Lectin from Crataeva tapia bark exerts antitumor, anti-inflammtory and analgesic activities
por: Araújo, Regina M. S., et al.
Publicado: (2011)

The Global Transcriptional Response of Isolated Human Islets of Langerhans to Glucagon-Like Peptide-1 Receptor Agonist Liraglutide
por: Zhao, Xiaoning, et al.
Publicado: (2012)

The impact of the glucagon‐like peptide 1 receptor agonist liraglutide on the streptozotocin‐induced diabetic mouse kidney proteome
por: Liljedahl, Leena, et al.
Publicado: (2019)

Effects of insulin and the glucagon‐like peptide 1 receptor agonist liraglutide on the kidney proteome in db/db mice
por: Liljedahl, Leena, et al.
Publicado: (2017)

Improved postprandial glucose metabolism in type 2 diabetes by the dual glucagon‐like peptide‐1/glucagon receptor agonist SAR425899 in comparison with liraglutide
por: Schiavon, Michele, et al.
Publicado: (2021)

Metformin exerts synergistic anti-proliferative effects with liraglutide in human umbilical vein endothelial cells (HUVECs)
por: Shadboorestan, Amir, et al.
Publicado: (2022)

Glucagon-like peptide-1 receptor agonist Liraglutide has anabolic bone effects in ovariectomized rats without diabetes.
por: Lu, Nan, et al.
Publicado: (2015)

Glucagon-like peptide-1 receptor agonist, liraglutide, attenuated retinal thickening in spontaneously diabetic Torii fatty rats
por: Inoue, Kazuho, et al.
Publicado: (2022)

Effects of the glucagon-like peptide-1 receptor agonist liraglutide in juvenile transgenic pigs modeling a pre-diabetic condition
por: Streckel, Elisabeth, et al.
Publicado: (2015)

The Glucagon-Like Peptide 1 Receptor Agonist Liraglutide Stimulates Mechanistic Target of Rapamycin (mTOR) Signaling via PKA And Akt
por: Le, Thao D V, et al.
Publicado: (2021)

Comparison of the glucagon‐like‐peptide‐1 receptor agonists dulaglutide and liraglutide for the management of diabetes in solid organ transplant: A retrospective study
por: Singh, Priyamvada, et al.
Publicado: (2020)

Protective role of frizzled-related protein B on matrix metalloproteinase induction in mouse chondrocytes
por: Bougault, Carole, et al.
Publicado: (2014)

Glucagon-Like Peptide-1 Receptor Agonists as Potential Myelination-Inducible and Anti-Demyelinating Remedies
por: Sango, Kazunori, et al.
Publicado: (2022)

Effect of the Glucagon-Like Peptide-1 Receptor Agonists Semaglutide and Liraglutide on Kidney Outcomes in Patients With Type 2 Diabetes: Pooled Analysis of SUSTAIN 6 and LEADER
por: Shaman, Ahmed M., et al.
Publicado: (2021)

The effect of glucagon‐like peptide‐1 receptor agonists liraglutide and semaglutide on cardiovascular and renal outcomes across baseline blood pressure categories: Analysis of the LEADER and SUSTAIN 6 trials
por: Leiter, Lawrence A., et al.
Publicado: (2020)

Expression and function of visfatin (Nampt), an adipokine-enzyme involved in inflammatory pathways of osteoarthritis
por: Laiguillon, Marie-Charlotte, et al.
Publicado: (2014)

Improvement of islet graft function using liraglutide is correlated with its anti‐inflammatory properties
por: Langlois, A, et al.
Publicado: (2016)

Novel GPR43 Agonists Exert an Anti-Inflammatory Effect in a Colitis Model
por: Park, Bi-Oh, et al.
Publicado: (2022)

PM426. Effect of a glucagon-like peptide 1 (GLP-1) receptor agonist, liraglutide, on cognition and body weight during antipsychotic treatment
por: Babic, I, et al.
Publicado: (2016)

Efficacy of the Glucagon-Like Peptide-1 Receptor Agonists Liraglutide and Semaglutide for the Treatment of Weight Regain After Bariatric surgery: a Retrospective Observational Study
por: Jensen, Anders Boisen, et al.
Publicado: (2023)

Anti-inflammatory and atheroprotective properties of glucagon
por: Osaka, Naoya, et al.
Publicado: (2020)

Analgesic and anti-inflammatory activity of Argyreia speciosa root
por: Bachhav, R.S., et al.
Publicado: (2009)

Robust anti‐obesity and metabolic effects of a dual GLP‐1/glucagon receptor peptide agonist in rodents and non‐human primates
por: Henderson, S. J., et al.
Publicado: (2016)

Analgesic and Anti-Inflammatory Activity of Pinus roxburghii Sarg.
por: Kaushik, Dhirender, et al.
Publicado: (2012)

Effects of liraglutide on postprandial insulin and glucagon responses in Japanese patients with type 2 diabetes
por: Matsumoto, Shinobu, et al.
Publicado: (2013)

Cartilage protective and anti-analgesic effects of ALM16 on monosodium iodoacetate induced osteoarthritis in rats
por: Choi, Doo Jin, et al.
Publicado: (2019)

Impact of glucagon-like peptide 1 receptor agonist liraglutide and dipeptidyl peptidase-4 inhibitor sitagliptin on bowel cleaning and gastrointestinal symptoms in type 2 diabetes
por: Tong, Yan, et al.
Publicado: (2023)

Effects of glucagon‐like peptide‐1 receptor agonists liraglutide and semaglutide on cardiovascular and renal outcomes across body mass index categories in type 2 diabetes: Results of the LEADER and SUSTAIN 6 trials
por: Verma, Subodh, et al.
Publicado: (2020)

The GLP-1 agonist, liraglutide, ameliorates inflammation through the activation of the PKA/CREB pathway in a rat model of knee osteoarthritis
por: Que, Qihong, et al.
Publicado: (2019)

Bioflavonoid exerts analgesic and anti-inflammatory effects via transient receptor potential 1 channel in a rat model
por: Zarei, Mohammad Mahdi, et al.
Publicado: (2022)

Use of Glucagon-Like-Peptide 1 Receptor Agonists and Risk of Fracture as Compared to Use of Other Anti-hyperglycemic Drugs
por: Driessen, Johanna H. M., et al.
Publicado: (2015)

Anti-obesity therapy for cardiovascular disease prevention: potential expected roles of glucagon-like peptide-1 receptor agonists
por: Sawami, Kosuke, et al.
Publicado: (2022)

Fibroblast growth factor-21 is required for weight loss induced by the glucagon-like peptide-1 receptor agonist liraglutide in male mice fed high carbohydrate diets
por: Le, Thao D.V., et al.
Publicado: (2023)

Liraglutide Has Anti-Inflammatory and Anti-Amyloid Properties in Streptozotocin-Induced and 5xFAD Mouse Models of Alzheimer’s Disease
por: Paladugu, Leela, et al.
Publicado: (2021)

Defining criteria for the introduction of liraglutide using the glucagon stimulation test in patients with type 2 diabetes
por: Kondo, Yoshinobu, et al.
Publicado: (2013)

Analogs of 6-Bromohypaphorine with Increased Agonist Potency for α7 Nicotinic Receptor as Anti-Inflammatory Analgesic Agents
por: Ivanov, Igor A., et al.
Publicado: (2023)

Analgesic, anti-inflammatory and anti-pyretic activities of Caesalpinia decapetala
por: Parveen, Amna, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_pl2tigv587tlt2fc2g58khpk26